Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for RD Cells (Muscle Rhabdomyosarcoma Cells, CCL-136)
- Two component formulation enhances lipid mediated transfection efficiency
- Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
- Kit includes Transfection Enhancer reagent and recommended transfection protocol
- High transfection efficacy in the presence of serum
- Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
- Reproducible transfection results
- Works well for standard reverse transfection and high-throughput applications
- Download RD CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for RD cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems RD Transfection Protocol: [PDF]
Download MSDS: [PDF]
RD Cell Line:
Rhabdomyosarcoma (RMS) is a rare form of pediatric cancer that develops from skeletal muscles, with embryonal rhabdomyosarcoma (ERMS) affecting children five and under and being the most common type. Approximately 350 new cases of rhabdomyosarcoma are detected every year in the United States, accounting for roughly 3% of all pediatric malignancies, as indicated by the American Cancer Society (ACS). The RD cell line is useful in preclinical research that aims to discover novel cancer drugs. The RD cell line was obtained from the muscle tissue of a 7-year-old Caucasian female with rhabdomyosarcoma and produces both myosin ATPase and myoglobin. In addition to being unstable, the RD cell line is susceptible to different viruses, such as vaccinia virus, herpes simplex virus, or human poliovirus 1. RD cells exhibit both spindle cell and large multinucleated cell morphology. Altogen Biosystems manufactures pre-optimized transfection kits with high transfection efficiencies, including the RD transfection kit for rhabdomyosarcoma cells.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into RD cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in RD cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into RD cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6901)
- 1.5 ml (Catalog #6902)
- 1.5 ml CRISPR (Catalog #2191)
- 8.0 ml (Catalog #7084)